Stay updated on Trametinib and Docetaxel for KRAS+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Trametinib and Docetaxel for KRAS+ NSCLC Clinical Trial page.

Latest updates to the Trametinib and Docetaxel for KRAS+ NSCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedA new version entry dated 2026-07-02 was added to the record history, updating the Study Status and Contacts/Locations sections (with an associated 2026-07-01 entry and a 444 marker). The 2026-06-15 entry was deleted.SummaryDifference0.1%

- Check15 days agoChange DetectedA new revision tag Revision: v3.6.3 was added to the record history and the older Revision: v3.6.0 tag was removed, updating the revision list shown for the study’s history.SummaryDifference0.0%

- Check22 days agoChange DetectedA new version entry (443) was added on 2026-06-12 introducing the Study Status and Contacts/Locations sections to the record history, and the last update date was set to 2026-06-15; a 2026-05-29 entry was removed.SummaryDifference0.1%

- Check29 days agoChange DetectedThe record history now shows that recruitment has ceased, indicating the study is no longer enrolling participants. The history also reflects a new revision (v3.6.0) and the removal of the prior revision (v3.5.5), indicating updates to the study documentation.SummaryDifference0.0%

- Check37 days agoChange DetectedRevision label updated from v3.5.4 to v3.5.5 on the page. This indicates a small internal update to the site's history display rather than changes to study information.SummaryDifference0.0%

- Check44 days agoChange DetectedNew history entries on 2026-05-28 and 2026-05-29 add core content for Contacts/Locations and Study Status (including an item labeled 442). The entry dated 2026-05-01 was removed from the history.SummaryDifference0.1%

Stay in the know with updates to Trametinib and Docetaxel for KRAS+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Trametinib and Docetaxel for KRAS+ NSCLC Clinical Trial page.